Upadacitinib for the treatment of psoriasiform and spongiotic dermatitis: A multicenter case series.

Competing Interests: Dr Strober is a consultant who has received honoraria from AbbVie, Acelyrin, Alamar, Alumis, Almirall, Amgen, Arcutis, Arena, Aristea, Asana, Boehringer Ingelheim, Kangpu Pharmaceuticals, Bristol Myers Squibb, Capital One, Celltrion, CorEvitas, Dermavant, Imagenebio, Janssen, Leo, Eli Lilly, Maruho, Okura, Meiji Seika Pharma, Protagonist, Monte Carlo, Takeda, Novartis, Pfizer, UCB Pharma, Rapt, Regeneron, Sanofi-Genzyme, SG Cowen, and Union Therapeutics; holds stock options in Connect Biopharma and Mindera Health; serves as a speaker for AbbVie, Arcutis, Dermavant, Eli Lilly, Incyte, Janssen, Regeneron, and Sanofi-Genzyme; acts as a scientific codirector (consulting fee) for the CorEvitas Psoriasis Registry; served as an investigator for CorEvitas Psoriasis Registry; and holds the position of Editor-in-Chief (honorarium) for the Journal of Psoriasis and Psoriatic Arthritis. Dr M. Shahriari is a consultant who has received honoraria from AbbVie, Bristol Myers Squibb, Dermavant, Janssen, Leo Pharma, Lilly USA, Novartis, Ortho Dermatologics, Sanofi-Genzyme, Regeneron, and UCB; serves as a speaker for AbbVie, Bristol Myers Squibb, Lilly USA, Janssen, Dermavant, and Leo Pharma; and served as investigator for AbbVie, CorEvitas Psoriasis Registry, Dermira, Cara, Dermavant, Novartis, Union, and Mindera. Dr N. Shahriari has no conflicts of interest to declare.